Through its rare kidney disease portfolio, Novartis is committed to exploring a range of treatment options with different modes of action to slow IgAN progression
Updated results from the four studies will be presented in Oral Reports or Posters at the ASCO Annual Meeting
The acquisition is immediately accretive and creates a compelling, single-stop, multi-continent partner for biopharma companies
Further strengthens BaseLaunch's global pharma industry partnerships
Phase I data for tuvusertib, lead asset from the company’s unique portfolio of DDR inhibitors
Acquisition will advance Merck’s integrated offering for viral vector manufacturing
Establishing Asymchem’s first manufacturing footprint in Europe
Operationally ready by 2029, it will be the Company’s first-ever facility to cover the full manufacturing process for ADCs
Sanofi will leverage this partnership to provide access to proprietary data to develop AI models
Subscribe To Our Newsletter & Stay Updated
